Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Apatinib Plus Chemotherapy in Advanced Breast Cancer After ADC Progression
NCT07907354Phase 2Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Mar 2027
- Primary completion
- Dec 2029
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in breast cancer, sponsored by Yunnan Cancer Hospital. Primary endpoint: Objective Response Rate up to 24 months. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07907354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07907354.